There have been massive improvements in treatments in the last 5 years. Sure, cancer is far from being "cured" - but survival today is far better than 5 years ago for many forms.
Among many others:
- CAR T therapy going from lab to oncology suite (first launch 2017, but use rapidly growing)
- Liquid biopsy going from lab to PCP's office - starting with Grail Galleri and moving from there (yes, the NIH results were weak, but the idea of a liquid biopsy at all would be laughed off 10 years ago)
- Move of Atezolizumab and Tecentriq from infusion (hour) to injection (minutes) to increase availability
- Lower dose CT scanning for lung cancer, including for non-smokers
And a long line of immunotherapies that are making the leap from lab to chair right now.
The last 5 years have probably been the most exciting in cancer research since the launch of the monoclonal antibodies in the early 2010s. There is still incredibly far to go, but the trend is in the right direction: https://employercoverage.substack.com/p/decline-in-cancer-mo...
Radar is ineffective underwater because the radio waves are absorbed by the water. That is why there's no radar in use on submarines.
Sonar is not a valid solution here because it annoys the whales. Or at least high-power sonar, as used by the military, does. It would defeat the point.
No jets use or have ever used leaded products. Jets run on Jet-A, which is a close relative of kerosene. It has never been leaded. The purpose of lead was to prevent cylinders from prematurely detonating ("knocking") in internal combustion engines. Jets do not have any cylinders to knock; the fuel burns continually in an open combustion chamber.
You may have been thinking of 100LL (100 Low Lead) fuel for piston engined planes. Many airports stopped selling 100LL in January of 2022. The FAA has approved a lead-free replacement in fuels like UL94 that are steadily replacing 100LL.
There's lots of room to nitpick the evidence, but the studies are published:
> The relationship between age and job performance for Air Traffic Control Specialists (ATCSs) is an issue that has been revisited many times over the past few decades (Trites, 1961; Trites & Cobb, 1962; Cobb, 1968; VanDeventer & Baxter, 1984). Researchers have consistently found a negative relationship between controller age and performance across studies that have used different ATCS options (enroute, terminal), career stages (age at entry into training,current age on the job), and criterion measures (on-the-job ratings, academy performance) (Trites, 1961;Trites & Cobb, 1962; Cobb, 1968; VanDeventer & Baxter, 1984).
After the pharmacies got sued for filling opiate prescriptions (which were written by abusive doctors, but the pharmacies are the ones who got sued)[1], is it any surprise that Xanax and Adderall are being limited? If pharmacies are at risk for filling prescriptions that are more complex than antibiotics, the end result is that they make it harder to fill them.
Among many others:
- CAR T therapy going from lab to oncology suite (first launch 2017, but use rapidly growing)
- Approval of Keytruda and similar for many additional forms of cancer (see the 2021-2026 milestones here: https://www.drugs.com/history/keytruda.html )
- Liquid biopsy going from lab to PCP's office - starting with Grail Galleri and moving from there (yes, the NIH results were weak, but the idea of a liquid biopsy at all would be laughed off 10 years ago)
- Move of Atezolizumab and Tecentriq from infusion (hour) to injection (minutes) to increase availability
- Lower dose CT scanning for lung cancer, including for non-smokers
And a long line of immunotherapies that are making the leap from lab to chair right now.
The last 5 years have probably been the most exciting in cancer research since the launch of the monoclonal antibodies in the early 2010s. There is still incredibly far to go, but the trend is in the right direction: https://employercoverage.substack.com/p/decline-in-cancer-mo...